Cargando…

2119. Predictive Value of the Immunodeficiency Scoring Index for COVID-19 Related Outcomes in Hematopoietic Transplant Recipients

BACKGROUND: The Coronavirus Disease 2019 (COVID-19) has significantly impacted cancer patients with some reported mortality as high as 25%. The Immunodeficiency Scoring Index (ISI) was developed as a prognostic tool in allogeneic hematopoietic cell transplant (allo-HCT) recipients with respiratory s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daher, Marilyne, Khawaja, Fareed, Angelidakis, Georgios, Rondon, Gabriella, Spallone, Amy, Ramdial, Jeremy, Ariza-Heredia, Ella, Shpall, Elizabeth, Chemaly, Roy F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752913/ http://dx.doi.org/10.1093/ofid/ofac492.1740

Ejemplares similares

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

940. The use of a commercially available CMV T Cell Immunity Panel to Assess the Risk of CMV Infections in Hematopoietic Cell Transplant Recipients with Low Level CMV Viremia
por: Khawaja, Fareed, et al.
Publicado: (2021)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience
por: Srinivasan, Krithika, et al.
Publicado: (2022)

1583. The Utility of the Immunodeficiency Scoring Index (ISI) to Predict Outcomes of Coronavirus (HCoV) Infections in Hematopietic Cell Transplant (HCT) Recipients
por: Khawaja, Fareed, et al.
Publicado: (2018)

15. Evaluation of Retained Immunity for Tetanus-Diphtheria and Pneumococcal Vaccines in Recipients of Cellular Therapies
por: Angelidakis, Georgios, et al.
Publicado: (2021)

Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention
por: Wilson Dib, Rita, et al.
Publicado: (2023)

Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
por: Khawaja, Fareed, et al.
Publicado: (2019)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection
por: Marinos, Alejandro, et al.
Publicado: (2023)

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
por: Khawaja, Fareed, et al.
Publicado: (2022)

Acute and latent viral infections in immunocompromised patients: a tale of brave battles and menacing foes
por: Spallone, Amy, et al.
Publicado: (2022)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients
por: Foolad, Farnaz, et al.
Publicado: (2017)

Utility of the Enzyme-Linked Immunospot Interferon-γ–Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2016)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned
por: Khawaja, Fareed, et al.
Publicado: (2023)

Transplant Providers’ Perceptions of COVID-19 Vaccination in the Wake of a Global Pandemic
por: Spallone, Amy, et al.
Publicado: (2022)

Surveillance and identification of clusters of healthcare workers with coronavirus disease 2019 (COVID-19): Multidimensional interventions at a comprehensive cancer center
por: Ariza-Heredia, Ella J., et al.
Publicado: (2020)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

2798. Respiratory Viral Infections in Patients with Lymphoma and Multiple Myeloma: Risk Factors Associated with Progression to Lower Respiratory Tract Infection and Mortality
por: Martinez, Daniel De La Rosa, et al.
Publicado: (2019)

Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
por: Vergidis, Pascalis, et al.
Publicado: (2017)

PReS-FINAL-2119: United Kingdom survey of current management of juvenile localised scleroderma
por: Hawley, DP, et al.
Publicado: (2013)

Origin and Evolutionary Dynamics of the miR2119 and ADH1 Regulatory Module in Legumes
por: De la Rosa, Carlos, et al.
Publicado: (2020)

2681. Outcomes Related to Respiratory Viral Infections in Cancer Patients on PD-1 Inhibitors
por: Khawaja, Fareed, et al.
Publicado: (2019)

PB2119: REDUCED OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS DURING THE COVID-19 PANDEMIC
por: Luchinin, Alexander, et al.
Publicado: (2023)

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
por: Khawaja, Fareed, et al.
Publicado: (2023)

The Successful Recovery of Bacteriophages with Activity against Vancomycin-Resistant Enterococci (VRE) from Stool Samples of Hematopoietic Cell Transplant (HCT) Recipients
por: El Haddad, Lynn, et al.
Publicado: (2017)

2730. Clinically significant cytomegalovirus infection in patients with lymphoma and no prior cellular therapy
por: Zubovskaia, Anna, et al.
Publicado: (2023)

KD025 (SLx-2119) suppresses adipogenesis at intermediate stage in human adipose-derived stem cells
por: Diep, Duy Trong Vien, et al.
Publicado: (2019)

Clinical and Economic Burden of Respiratory Viral Infections in Hematopoietic Stem Cell Transplant Recipients: The MD Anderson Experience
por: Ghantoji, Shashank S, et al.
Publicado: (2017)

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
por: Waghmare, Alpana, et al.
Publicado: (2020)

Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs
por: Wu, Kevin, et al.
Publicado: (2023)

2119. Matched-Paired Analysis of Patients Treated for Invasive Mucormycosis—Standard Treatment vs. Posaconazole New Formulations (MoveOn)
por: Salmanton-Garcia, Jon, et al.
Publicado: (2019)

COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Sharma, Akshay, et al.
Publicado: (2021)

1120 The Impact of Influenza Vaccination in Patients with Cancer on Subsequent Disease during the 2013-2014 Influenza Season
por: Azzi, Jacques, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4m2h350cm4u4g18kv3vuguakf3